Cellular Allogeneic Bone Graft

Similar documents
At the conclusion of this lesson you should be able to:

Background. Background. Background. Background. Background 3/4/2013

PRIME-XV Cell Therapy Products by

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:

Tissue Engineered Medical Products

PTH Effects Bone Healing and Vasculogenesis in Calvaria Bone Allograft Model

A Comparative Study of Upconverting Nanoparticles Versus Lentiviral GFP Transduction for Labeling Mesenchymal Stem Cells

Xeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications

Introduction to Cell- Biomaterial Engineering!

YOUR OWN LIFE

THE NANOSCALE WORLD OF SPINAL FUSION

Osteogenic Differentiation and Analysis of MSC

Antibody-based HLA (Human Leucocyte Antigen ) tissue-typing technologies

The Role of Adult Stem Cells in Personalized and Regenerative Medicine

Project Proposal Ultrasound Mediated Tissue Engineering Project Team 21

Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords

Discover TruPRP. PRP the way you want it.

UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE

Functional Assessment and Clinical Outcome

Regenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016

Structural Assessment of a Tissue Engineered Scaffold for Bone Repair

What Are Stem Cells? Where Are These Stem Cells?

Formation of Mesenchymal Tissues in Alvetex Scaffold Derived From Stem Cells and Established Cell Lines. Introduction

ANAT 3231 Cell Biology Lecture 21 Stem Cells

Des cellules-souches dans le poumon : pourquoi faire?

PEEK-OPTIMA HA ENHANCED. Advancing the Science of Fusion

Contents. The Right Surface for Every Cell Extracellular Matrices and Biologically Coated Surfaces ECM Mimetic and Advanced Surfaces...

The Power in You. TM

PRO-STIM Injectable Inductive Graft Containing DONATED HUMAN TISSUE

Department of Metallurgy and Materials Engineering, Katholieke Universiteit Leuven, B Leuven, Belgium; 2

colorimetric sandwich ELISA kit datasheet

Forefoot. Foot & Ankle. Foot & Ankle. Midfoot. Bone Graft Substitutes Soft Tissue Repair. Rearfoot. Ankle

Immunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications

Philadelphia College of Osteopathic Medicine Annual Progress Report: 2010 Formula Grant

User Manual. OriCellTM Strain C57BL/6 Mouse Mesenchymal Stem Cells with RFP(MSCs/RFP) Cat. No. MUBMX-01201

Fundamental properties of Stem Cells

VIII. Validation Evaluation Comparative Chart Application Fields of PRP Advantages of MiroPRP for skin treatments MicroPRP and Mico-Mesotherapy

Bioreactors in tissue engineering

ANAT 2341 Embryology Lecture 18 Stem Cells

Design Of A Modular Endothelialized Platform For Vascularized Bone Regeneration

RegenACR. autologous cellular regeneration. RegenACR A-PRP treatment. collagen fibers. 1,2 texture and elasticity. 3 volume & strength.

Detection and Quantification of Human Bone Morphogenetic Protein 7 (hbmp-7) Concentrations in Cell Lysates, Sera and Plasma.

BD MOSAIC h MSC CELL CULTURE ENVIRONMENT DEFINED SERUM FREE

Accumax Cell Dissociation Solution

The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis

Mouse VEGF ELISA. Cat. No: KB2155 Ver3.0 RUO. ELISA for Accurate Quantitation from Cell Culture Supernatant, Serum, Plasma, or Other Bodily Fluids

T ECHNICAL MANUAL. Culture of Human Mesenchymal Stem Cells Using MesenCult -XF Medium

ABSTRACTS Current challenges for materials for orthopedic implants Theofilos Karachalios

Disclosures. New therapies for spinal fusions. Cells, Molecules and Surfaces" Hyun Bae, MD

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)

Kuros Biosciences AG «A new era in Bone Regeneration»

Expansion of Human Mesenchymal Stem Cells Using Corning HYPER Technology Cell Culture Vessels

Gene Therapy Applications for Fracture Repair

UNTHSC Scholarly Repository. University of North Texas Health Science Center

MSD MULTI-SPOT Assay System

Facts and theories of organ regeneration in adults

STEM CELLS BONE FRACTURE

InVivo Therapeutics. Developing Innovative Products for Spinal Cord Injury

Regenerative medicine approaches to the treatment of cardiovascular disease

For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine.

Rat TNF-α ELISA REF. Ver5.0 RUO. ELISA Set for Accurate Quantitation from Cell Culture Supernatant, Serum, Plasma or Other Bodily Fluids

High Throughput Quantitation of Cytokine Biomarkers using LANCE Ultra TR-FRET Assays

SUPPLEMENTARY INFORMATION

Stem Cell Services. Driving Innovation for Stem Cell Researchers

Blue Marble University Biology Course Handbook

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation

In vivo safety and efficacy testing of a thermally triggered injectable hydrogel scaffold for bone regeneration and augmentation in a rat model

Amaxa 4D-Nucleofector Protocol for Undifferentiated Human Mesenchymal Stem Cells [MSC] For 4D-Nucleofector X Unit Transfection in suspension

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

Regenerative Medicine for Joint Disease. Regenerative Medicine for Joint Disease. Regenerative Medicine for Joint Disease

Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. JournalClub Emilie Hrdliczka

In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells Ningfei An, Yubin Kang *

Table of Contents 1.0 Introduction Thawing Cells, Plating and Colony Enumeration...2

Adult Stem Cells by David A. Prentice, Ph.D.

Clinical Applications of Mesenchymal Stromal Cells

Human Granulin / GRN / Progranulin ELISA Pair Set

Life Sciences. Novel ECM Mimetic Surfaces for Cell Expansion and Differentiation

Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation

Mouse ICAM-1 / CD54 ELISA Pair Set

Over the past decade, autologous and allogeneic grafts

CRANIOS REINFORCED BONE VOID FILLER

Stem Cells and Regenerative Medicine

MagniSort Mouse Hematopoietic Lineage Depletion Kit Catalog Number: RUO: For Research Use Only. Not for use in diagnostic procedures.

leading the way in research & development

Tissue Products Catalogue

Human IL-6 ELISA Kit. User Manual (Revised Dec 16, 2009) Human IL-6 ELISA Kit Protocol. (Cat#: RAY-ELH-IL6-001)

Human IL10RB ELISA Pair Set ( CRFB4 )

NORIAN DRILLABLE TECHNICAL MONOGRAPH. Fiber reinforced calcium phosphate phate bone void filler

Transcription:

Cellular Allogeneic Bone Graft Technical Brochure Strips Allograft Chips Allograft

Contents Page 1. Properties of Bone Formation...3 2. Stem Cells and Bone Repair...4 3. Multipotent Adult Progenitor (MAPC )-Class Cells...5 a. MAPC-Class Cells Differentiation Potential...5 b. MAPC-Class Cells Osteogenic Potential...7 c. MAPC-Class Cells Angiogenic Properties...8 d. MAPC-Class Cells Immunomodulatory Properties...12 4. Pre-Clinical Data: In Vivo Bone Formation...14 a. In Vivo Osteogenicity Model...14 b. Evaluation of Bone Formation in a Rat Posterolateral Fusion Model...15 c. Evaluation of Bone Formation in a Rabbit Posterolateral Fusion Model...16 d. Evaluation of Bone Formation in a Sheep Critical Sized Defect Model... 17 5. map3 Cellular Allogeneic Bone Graft...19 6. The map3 Allograft Difference...20 7. Focus on Cell Viability...21 8. Safe and Reliable Process From Donor Selection through Implant Release...22 9. Ordering Information...23 2

Properties of Bone Formation The process of bone formation is driven by these main elements: > Osteoconduction > Osteoinduction > Osteogenesis > Angiogenesis An ideal bone graft substitute provides all the necessary elements of bone formation in a single allograft. Autogenous bone graft includes the elements necessary to promote bone growth-scaffolding for osteoconduction, growth factors for osteoinduction and viable cells for osteogenesis. Ideally, a bone graft substitute should do the same. 1,2 Traditionally, osteoconduction, osteoinduction and osteogenesis have been considered the most important elements for new bone formation. Moreover, it is widely known that angiogenesis also plays a very important role in bone repair. 3 New blood vessel formation allows for the migration of cells and necessary nutrients to the site of injury. Studies have shown that inhibition or promotion of vessel formation in an injury model can impact bone healing and that health factors that negatively impact neovascularization (e.g. smoking or diabetes) can cause delayed fracture healing or result in non-unions. 4,5,6 Osteoconduction Osteoinduction BONE FORMATION Angiogenesis Osteogenesis Figure 1. Main elements involved in the bone formation process. 1 A. R. Vaccaro. The role of the osteoconductive scaffold in synthetic bone graft. Orthopedics 2002; 25(5): s571-s578 2 P.G. Whang and J.C. Wang. Bone graft substitutes for spinal fusion. The Spine Journal 2003; 3: 155-165 3 K.D. Hankenson. Angiogenesis in bone regeneration. Injury 2011; 42(6): 556-561 4 C. Lu, et al. Assessing angiogenesis during fracture healing. The Iowa Orthopaedic Journal 2006; 26: 17 26 5 T. Anderse, et al. Smoking as a predictor of negative outcome in lumbar spinal fusion. Spine; 2001 26(23):2623-2628 6 H. Lu, et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003; 144(1): 346-352 3

Stem Cells and Bone Repair Figure 2. Stem cells play several roles in the healing response throughout our lifetime. They respond to local environmental stimuli in order to differentiate and replace damaged cells or rebuild injured tissue. They also serve a signaling role themselves. Specialized Cells Signaling from other cells or specific environmental stimuli can lead to stem cell differentiation. Stem Cell Specialized Cell Signaling by the stem cells recruits specialized cells to areas where healing is necessary. Stem cells play several roles in the healing response: > Respond to local environmental cues in order to differentiate and replace damaged cells or rebuild injured tissue. > Signal and recruit host cells to participate in the healing response. > Provide angiogenic stimuli. Autologous sources of stem cells can be variable and are dependent on the age and health of the patient. Cellular bone grafts, which contain a reliable source of viable stem cells, are an ideal alternative for traditional bone grafting. A stem cell is a primitive cell that has the ability to self-renew and differentiate into multiple specialized cell types. These cells are able to divide and replenish other cells in the body throughout our life span. Stem cells remain uncommitted until specific signals induce them to differentiate into various tissue types. Stem cells play an important role in the natural healing process. This is done by either differentiating into specialized tissues themselves, or signaling the necessary host cells to participate in the healing process. Although autograft and bone marrow aspirate have traditionally been used as a source of live cells for bone grafting, this is not always a viable option. The concentration of stem cells from autologous sources is variable and dependent on the age and health of the patient, as well as the collection site. 7 It is well documented in the literature that as we age, there is a natural decrease in the concentration of available stem cells. 8 Because of this, cellular allogeneic bone grafts, which contain a reliable source of viable stem cells, are an ideal alternative for traditional bone grafting. 7 Mesenchymal stem cell content of human vertebral bone marrow. Ahrens N., et al. Transplantation 2004; 78(6): 925-29 8 Age- and gender- related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. Muschler GF., et al. Journal of Orthopaedic Research 2001; 19: 117-125 4

Multipotent Adult Progenitor (MAPC )-Class Cells MAPC-Class Cells Differentiation Potential MAPC-class cells have the ability to form any of the three germ layers: mesoderm, ectoderm and endoderm. (Diagram 1) Since the cells are multipotent in nature, they have the capability to differentiate along the chondrogenic, adipogenic or osteogenic lineage (mesoderm layer). MAPCclass cells were cultured under appropriate conditions for each lineage and stained with oil red O, alizarin red or toluidine blue to confirm differentiation along the respective lineages. A B C D Figure 3. Immunocytochemistry of MAPC-class cells along each differentiation lineage. (A) MAPC-class cells cultured on a tissue culture plate (20x); (B) Oil red O stained positive for fat accumulation, indicative of adipogenic differentiation (20x); (C) Alizarin red stained positive for calcium deposits/mineralization, indicative of osteogenic differentiation (20x); (D) Toluidine blue stained positive for cell aggregate for cartilage, indicative of chondrogenic differentiation (5x). 5

MAPC-Class Cells Have the Ability to Form Any of the Three Germ Layers Ectoderm (external layer) Skin cells Neural cells Lens cells (eye) Mesoderm (middle layer) Fat cells Bone cells Cartilage cells Endoderm (internal layer) Pancreatic cells Small intestine cells Kidney cells Diagram 1. The diagram above depicts the three primary germ layers in vertebrates and illustrates examples of cell types that are found in each of the germ layers. A germ layer is a primary layer of cells that forms during embryogenesis. 6

MAPC-Class Cells Osteogenic Potential MAPC-class cells have demonstrated osteogenic potential in vitro. The osteogenic potential of the cells was assayed by looking at the presence of alkaline phosphatase, as well as the presence of mineral deposits. Figure 4. Alkaline phosphatase expression by MAPC-class cells cultured in (A) control or (B) osteogenic media for eight days. Fast blue staining indicated the presence of alkaline phosphatase activity only in cells cultured in osteogenic media (B). A MAPC-class cells in control media B MAPC-class cells in osteogenic media Alkaline phosphatase is an early indicator of active osteoblasts. Positive fast blue staining indicates the presence of alkaline phosphatase activity. Figure 5. Mineral production by MAPC-class cells cultured in (A) control or (B) osteogenic media for 21 days. Alizarin red staining indicated the presence of mineral deposits only in cells in osteogenic media (B). A MAPC-class cells in control media B MAPC-class cells in osteogenic media Mineralization and calcium deposits are late markers of osteogenicity. Positive alizarin red staining indicative of MAPC-class cells producing calcium deposits. 7

MAPC-Class Cells Angiogenic Properties MAPC-class cells exhibit angiogenic properties that promote new vessel formation in vitro and in vivo (in a mouse model*) to a greater extent than mesenchymal stem cells (MSCs). Angiogenic Protein Production by MAPC-Class Cells MAPC-class cells secreted specific angiogenic cytokines (IL-8 and CXCL-5) at higher levels when compared to MSCs. 8000 6000 4000 pg/ml 2000 1500 1000 500 Figure 6. Angiogenic cytokine secretion by MAPC-class cells and MSCs assayed via ELISA. Results demonstrated that MAPC-class cells secrete specific angiogenic cytokines at higher levels when compared to MSCs. IL-8: Interleukin 8 0 IL-8 CXCL5** CXCL5: Epithelial derived neutrophil-activating peptide 78 MAPC-Class Cells **CXCL5 concentration was below detectable levels for MSCs MSC An enzyme-linked immunosorbent assay (ELISA) was used to quantify the production of specific angiogenic cytokines by MAPC-class cells. Levels of angiogenic cytokines secreted by mesenchymal stem cells (MSCs) were assayed as well and compared to those of MAPC-class cells. Quantified production levels for IL-8 were significantly higher for MAPC-class cells, (p<0.005) when compared to MSCs. Furthermore, CXCL5 production levels were substantial for MAPC-class cells but undetectable for MSCs. * Performance data from animal studies may not be representative of performance in humans. 8

MAPC-Class Cells Induce Vessel Formation by Endothelial Cells in an In Vitro Tube Formation Assay MAPC-class cells produced angiogenic cytokines which influenced endothelial cells to form tube-like structures in a three-dimensional matrix. Tube formation in the samples treated with MAPC-class cells conditioned media appeared more dense and well defined than those treated with MSCs. A B Figure 7. Endothelial cell growth under four separate conditions evaluated in the tube formation assay. (10x) (A) Negative control media; (B) Positive control media; (C) MSCs conditioned media; (D) MAPC-class cells conditioned media. Exposure to MAPC-class cells conditioned media (D) induced the formation of a dense network of vessel-like structures by the endothelial cells. C D The addition of MAPC-class cells-conditioned media to endothelial cells in culture (Figure 7D) induced the appearance of a dense web-like structure, similar to that observed in the positive control group (Figure 7B). This finding is indicative of MAPC-class cells releasing crucial angiogenic growth factors that induce the formation of vessel like structures by endothelial cells. 9 The MAPC-class cell group had denser and more well-defined tube formations when compared to MSCs (Figure 7C). 9 Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Lehman N, Cutrone R, Raber A, Perry R, Van t Hof W, Deans R, Ting AE, Woda J. Cytotherapy. 2012 Sep; 14(8): 994-1004. 9

In Vivo Evaluation (Mouse Model*) Comparing Blood Vessel Formation in TCP with MAPC-Class Cells vs. TCP Alone Resulted in: 131% increase in new blood vessel formation with the addition of MAPC-class cells to TCP cubes (compared to the TCP alone). 29% increase in new blood vessel formation with MAPC-class cells over scaffold seeded with MSCs. Porous ceramic tri-calcium phosphate cubes were incubated with a suspension of MAPC-class cells or mesenchymal stem cells (MSCs). Cell-loaded cubes and cell-free cubes were implanted subcutaneously into NOD/SCID mice, harvested at seven weeks post-implantation, stained and histologically evaluated for bone deposition and vessel formation. Histologically, new bone formation and abundant new blood vessel formation were noted in MAPC-class cell-loaded cubes. The histological scores associated with new bone formation were 32% for MAPC-class cell-loaded, 27% for MSC-loaded and 0% for cell-free cubes. Moreover, new blood vessel formation was quantified. Ceramic cubes loaded with MAPC-class cells resulted in significantly (p<0.05) more vessel formation in the implant when compared to that of cell-free cubes, namely a 131% increase. In addition, cubes loaded with MAPC-class cells resulted in significantly (p<0.01) greater new vasculature when compared to the MSC-loaded cubes, namely a 29% increase. A B C TCP Alone TCP + MSCs TCP + MAPC-Class Cells Figure 8. Masson s trichrome histological images at 100x magnification showing remodeling of the (A) empty ceramic cubes; (B) MSC-loaded ceramic cubes and (C) MAPC-class cell-loaded ceramic cubes. Note the abundant vessel and new bone formation in the MAPC-class cell-loaded cubes. NB = new bone, TCP = tricalcium phosphate cube particles. Black arrows point to blood vessels. * Performance data from animal studies may not be representative of performance in humans. 10

Synergistic Effect of Culturing MAPC-Class Cells with an Osteoinductive Scaffold (DBM) 6000 5000 VEGF (pg/ml) 4000 3000 2000 1000 0 3 7 10 14 Time (days) Cells Cells + DBM Transwell DBM Figure 9. Vascular Endothelial Growth Factor (VEGF) protein release over a course of 14 days as assayed via ELISA. MAPC-class cells produced high quantities of VEGF. When MAPC-class cells were cultured in close proximity to DBM, VEGF production was significantly increased. MAPC-class cells produced VEGF when cultured on a culture plate. The amount of VEGF produced increased when the MAPC-class cells were cultured with DBM. MAPC-class cells were added to individual wells of a 24-well culture plate containing a transwell insert either with or without 50 mg of demineralized bone matrix (DBM; 2 lots). A cell-free group containing only an insert of DBM was also prepared. All groups were cultured in triplicate in osteogenic media for 14 days. VEGF was measured using an ELISA assay from supernatants collected after various time points. VEGF release was low for the DBM alone sample. MAPC-class cells produced high levels of VEGF independently; however, when they were cultured with the DBM scaffold, the VEGF levels increased synergistically. 11

MAPC-Class Cells Immunomodulatory Properties The natural healing process begins with inflammation and is followed by regeneration and remodeling. Inflammation is a result of the immune reaction that is initiated with any infection or injury. Although inflammation is a critical component of regeneration, a prolonged inflammatory response can have negative effects on the rate and quality of healing and lead to the formation of fibrotic or scar tissue. MAPC-class cells have been shown to affect both the inflammatory process as well as the immune response in specific ways. TNFα (pg/ml) 1000 800 600 400 200 Attenuated Inflammatory Response MAPC-class cells have shown potential for reducing local inflammation by regulating the production of inflammatory cytokines. Expression of the pro-inflammatory cytokine TNF was downregulated in the presence of MAPC-class cells conditioned media. 0 Activated WBC Activated WBC + MCM WBC: White blood cells MCM: MAPC-class cells conditioned media Figure 10. Lipopolysaccharides (LPS) were used to activate white blood cells (THP-1) which in response secrete pro-inflammatory signals such as TNF. MAPC-class cell-conditioned media contains signals that attenuate the inflammatory response and reduce the production of TNF by the activated white blood cells. To study the immunomodulatory properties of MAPC-class cells, THP-1 cells were activated and induced to produce the inflammatory cytokine TNF. An ELISA assay was used to quantify TNF production levels. THP-1 cells alone had a heightened immune response as evidenced by the increased production of TNF. The experimental group, in which the THP-1 cells were cultured in MAPC-class cell-conditioned media (MCM), exhibited a reduction in the production of TNF. 12

Following pro-inflammatory signals, white blood cells, such as T-cells, get activated and recruited to the injury site to participate in the immune response. MAPC-class cells exhibited immunomodulatory functions and were able to suppress activated T-cell proliferation in vitro. MAPC-class cells have been shown to be non-immunogenic. Thymidine Incorporation (CPM) 70000 60000 50000 40000 30000 20000 10000 0 PBMC Activated PBMC Activated PBMC + MAPC- Class Cells Immunomodulatory Properties MAPC-class cells have been shown not to elicit an immune rejection response and attenuated the proliferation of T-cells. Figure 11. Activated peripheral blood mononuclear cells (PBMCs) cultured with MAPC-class cells. Thymidine incorporation counts were used to determine the rate of actively proliferating T-cells. MAPC-class cells have been shown not to elicit an immune response and attenuated the proliferation of T-cells in an activated PBMC sample. Peripheral blood mononuclear cells (PBMCs) were cultured in a mixed lymphocyte reaction (MLR) assay. PBMCs alone did not elicit a T-cell response. Stimulatory cytokines (CD3/CD28), which serve as signals to trigger an immune response, were used to activate PBMC cultures. Activated PBMCs showed an increase in the amount of viable T-cells as evidenced by the high thymidine incorporation counts indicative of active T-cell proliferation. Activated PBMCs co-cultured with MAPC-class cells exhibited a significant reduction in T-cell proliferation. By modulating inflammatory signals and the proliferation of active immune cells, the immune response may be diminished, and the regeneration process can begin more promptly. MAPC-class cells have been demonstrated to be non-immunogenic. MAPC-class cells do not express MHC class II antigens and should not be recognized as foreign by the immune system. Isolation of the MAPC-class cells selects against hematopoietic cells and other cells that express HLA antigens and could cause an immune response. Testing is performed on every lot to ensure the absence of these contaminating cells. 13

Pre-Clinical Data: In Vivo Bone Formation MAPC-class cell-loaded scaffolds provided the necessary elements for new bone formation, demonstrating in vivo osteogenicity. The results of these studies show evidence of in vivo bone formation across four different animal models.* In Vivo Osteogenicity Model* Methods: Implanted subcutaneously into NOD/SCID mice. Seven-week duration. Treatment groups: > TCP cubes alone or in combination with MAPC-class cells. A TCP Alone B TCP + MAPC-Class Cells Figure 12. Masson s trichrome histological images at 100x magnification showing remodeling of (A) the empty ceramic cubes and (B) MAPC-class cell-loaded ceramic cubes. Note the abundant vessel and new bone formation in the MAPC-class cellloaded cubes. NB = new bone TCP = tricalcium phosphate cube particles Black arrows point to blood vessels Results: New bone formation was evident in all of the MAPC-loaded cubes after seven weeks. No new bone matrix detected in the cell-free cubes. *Performance data from animal studies may not be representative of performance in humans. 14

Evaluation of Bone Formation in a Rat Posterolateral Fusion (Spinal Fusion) Model* Methods: L4 and L5 posterolateral fusion in rats. Six-week duration. Treatment groups: > DBM** alone or in combination with MAPC-class cells. Figure 13. Masson s trichrome histological images at 20x magnification showing fusion mass from the sites treated with (A) DBM alone or (B) DBM with cells. In both cases the implants were substantially remodeled into new bone (circled in solid yellow) resulting in spinal fusion. However, increased overall remodeling was associated with the cell loaded scaffold (B) as indicated by the areas bounded in dashed yellow lines that show the original unremodeled DBM. Solid yellow line = Area remodeled into new bone Dotted yellow line = Original, unremodeled DBM A B DBM Alone DBM + MAPC-Class Cells **Rabbit DBM Results: The MAPC-class cell-loaded DBM scaffold had a significantly (p<0.05) higher histologic score, more new bone and less fibrous tissue compared to the DBM scaffold alone. Bridging was achieved between L4-L5 after six weeks. *Performance data from animal studies may not be representative of performance in humans. 15

Evaluation of Bone Formation in a Rabbit Posterolateral Fusion (Spinal Fusion) Model* Methods: L4 and L5 posterolateral fusion in rabbits. Five week duration. Treatment groups: > DBM** in combination with MAPC-class cells compared to morselized autograft iliac crest. A B Autograft DBM + MAPC-Class Cells Figure 14. H&E stained histological images at 100x magnification showing implanted graft remodeling. Both grafts were actively involved in remodeling. However, there was more new bone (NB) and less fibrotic tissue (FT) noted in cell-loaded DBM group, (B) indicative of advanced remodeling. NB = new bone RG = residual graft BM = bone marrow FT = fibrous tissue Black arrows point to new blood vessels, blue arrows point to osteoblasts and green arrows point to osteoclasts. **Rabbit DBM Results: DBM loaded with MAPC-class cells had significantly (p<0.05) higher histologic score and less fibrous tissue than the autograft group. Bridging bone indicative of fusion was observed after five weeks. *Performance data from animal studies may not be representative of performance in humans. 16

Evaluation of Bone Formation in a Sheep Critical Sized Defect Model* (Femur Critical Sized Defect) Methods: Critical defect wound (15mm diameter x 15mm depth) in sheep. Six-week duration. Treatment groups: > TCP granules in combination with MAPC-class cells compared to morselized sheep autograft iliac crest. A B Autograft TCP + MAPC-Class Cells Figure 15. H&E histological images at 100x magnification showing a critical defect filled with either (A) autograft or (B) TCP granules loaded with MAPC-class cells. NB = new bone FT = fibrous tissue BM = bone marrow RG = residual graft. Results: The area between the MAPC-class cell-loaded TCP granules was filled with new bone after six weeks. There was less bone and more fibrous tissue in the autograft treated defects. *Performance data from animal studies may not be representative of performance in humans. 17

Designed by nature, supported by science 18

map3 Cellular Allogeneic Bone Graft A Natural and Safe Alternative to Autograft 1. Cortical-cancellous bone chips provide a three-dimensional osteoconductive scaffold to support cellular infiltration and attachment Figure 16. map3 Chips scaffold 2. Demineralized bone matrix (DBM) demonstrates verified osteoinductive potential* Figure 17. Histological image (H&E, 100x) of DBM assayed in vivo in an athymic nude rat assay and determined to have osteoinductive potential. NB = new bone BM = bone marrow DBM = residual DBM 3. Cryogenically preserved, viable multipotent adult progenitor (MAPC )- class cells provide osteogenic and angiogenic signals to support bone healing process Figure 18. Masson s trichrome histological images (100x) showing remodeling of MAPCclass cell loaded ceramic cubes in a mouse model.** NB = new bone TCP = tricalcium phosphate cube particles Black arrows point to blood vessels * DBM or representative finished implant is either assayed in vivo in the modified athymic nude rat model for bone formation or in vitro for endogenous BMP-2 as a surrogate test marker for osteoinductive potential. Because the combination of various proteins is responsible for osteoinductive potential, DBM when assayed in vitro, is also screened for the presence of BMP-7. Findings from an in vitro assay or animal model are not necessarily predictive of human clinical results. **Performance data from animal studies may not be representative of performance in humans. 19

The Difference A natural and safe alternative to autograft that provides a streamlined approach to bone grafting. A Natural and Safe Alternative to Autograft Three (3) elements of bone formation in a single allograft. Mineralized cortical cancellous bone chips provide an osteoconductive scaffold. Demineralized bone matrix (DBM) demonstrates verified osteoinductive potential. Cryogenically preserved viable multipotent adult progenitor (MAPC)- class cells provide proven osteogenic, and angiogenic signals to support the bone healing process. Focus on Cell Viability A minimum of 50,000 viable MAPCclass cells/cc of implant are present on the scaffold at the time of implantation. Donors are carefully selected for optimal cell quality. Cell viability is confirmed at multiple points during the isolation process and validated for the graft s shelf life. Recovery and isolation processes are designed to ensure optimal cell viability. Easy to Use Simple and straightforward preparation steps. Multiple configurations and sizes provide unique handling characteristics and versatility. Strips Allograft: Comprised of a three-dimensional scaffold, DBM and cryogenically preserved MAPC-class cells. Moldable implant with flexible yet cohesive properties making it ideal for filling bone voids in applications such as small joint repair, irregular defects or as an onlay in the posterolateral spine. Chips Allograft: Comprised of DBM, cortical cancellous bone chips and cryogenically preserved MAPC-class cells. Available for applications such as filling bony defects and packing cages. 20

Focus on Cell Viability A minimum of 50,000 viable MAPC-class cells/cc of implant are present on the scaffold at the time of implantation. All aspects of processing have been carefully designed and tested to protect cell viability. The minimum number of cells is validated over the implant s shelf life. Proprietary MAPC-Based Technology Isolation Process: Maintains healthy cells without altering their innate biological properties. Cell type confirmed via lot release testing which includes verification of surface markers and angiogenic cytokines. Carefully controlled rate-cooling process after isolation preserves cell viability through implantation. Reliable Cell Viability and Cell Number In vivo cell tracking MAPC-class cells are still present at the surgical site for at least 10 days after implantation. Figure 20. Micrograph of viable fluorescently (calcein) stained MAPC-class cells attached to the map3 Chips scaffold. MAPC-Class Cells Figure 19. Rat* MAPC-class cells on a DBM scaffold implanted into a fibular critical defect and imaged 10 days post operatively. In order to provide a reliable minimum number of viable cells at implantation the viability losses due to cryopreservation, transportation and end user preparation of the cells must be understood and minimized. Starting with quantifying viable cells at isolation, cell viability measurements taken after the preservation, transportation, storage and implant preparation processes were used to determine a specific vialing concentration which ensures that each map3 allograft provides the targeted number of viable stem cells: 50,000 MAPCclass cells/cc of implant are present on the scaffold at the time of implantation. *Performance data from animal studies may not be representative of performance in humans. 21

Safe and Reliable Process from Donor Selection through Implant Release Map3 cellular allogeneic bone grafts have passed biocompatibility testing and are non-immunogenic, non-tumorigenic and safe. Studies have shown that animals injected with MAPC-class cells did not develop tumors and did not show heterotopic bone formation.* Donor infectious disease testing includes but is not limited to: Implant cell component safety is ensured through lot release testing which includes: Sterility testing based on methods outlined in USP <71>. Endotoxin testing based on methods outlined in USP <85>. Mycoplasma testing based on methods outlined in USP <63>. HCV Antibody HBV Surface Antigen HIV I & II Antibody HBV Total Core Antibody Syphilis HTLV I & II Antibody HIV-1/NAT HCV/NAT Donor qualification is a rigorous, multi-step process that includes screening, testing and final determination of donor eligibility. The final determination of donor eligibility is made by RTI Surgical s medical director a licensed physician utilizing all available, relevant information. Implant scaffold components are sterilized through the BioCleanse Tissue Sterilization Process or Cancelle SP DBM Sterilization Process as indicated. Where indicated sterile, processes applied achieve a Sterility Assurance Level of 10-6 via terminal sterilization. *Data on file at RTI Surgical, Inc. 22

cellular allogeneic bone graft is available in multiple configurations and a variety of sizes. Strips Allograft The Strips Allograft is comprised of a three-dimensional scaffold, DBM and cryogenically preserved MAPC-class cells. Map3 Strips are available as a 2cc strip, 5cc strip and 10cc skinny strip. The 10cc size includes two strips per package. Code Description Strips Allograft M3S002 M3S005 M3S010 map3 Strips Allograft, 2cc, 15 x 15 x 8 mm map3 Strips Allograft, 5cc, 25 x 25 x 8 mm map3 Strips Allograft, 10cc, 50 x 15 x 7 mm (2 each) Chips Allograft The Chips Allograft is comprised of cortical cancellous bone chips, demineralized bone matrix and cryogenically preserved MAPC-class cells. Map3 Chips are available in three sizes: 2cc, 5cc and 10cc. Code Description Chips Allograft M3C002 M3C005 M3C010 map3 Chips Allograft, 2cc map3 Chips Allograft, 5cc map3 Chips Allograft, 10cc RTI Surgical provides a focused team of product managers and biologics representatives for your support. Our dedicated customer service team is available 24 hours a day, 7 days a week, 365 days a year. To order, call RTI Customer Service Sports & Extremities: 800.624.7238 Spine: 888.778.8771 23

RTI Surgical, Inc. 11621 Research Circle Alachua, FL 32615 indicates U.S. registration. All trademarks and/or images are the property of their respective owners or holders. 8678 R0 05/15/15